Alessandra Cesano
CIK: 0001827015
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (13 total)
- Sep 14, 2026PBYI
PUMA BIOTECHNOLOGY, INC.
Exercise(M)Direct50K shares at avg. $2.93$147K - Sep 14, 2026PBYI
PUMA BIOTECHNOLOGY, INC.
Sale(S)Direct62.2K shares at avg. $9.12$567K - Jun 11, 2026PBYI
PUMA BIOTECHNOLOGY, INC.
Award(A)Direct27K shares- - Jan 12, 2026ZYME
Zymeworks Inc.
Award(A)DirectStock Option (Right to Buy)
11.5K shares- - Jan 12, 2026ZYME
Zymeworks Inc.
Award(A)DirectRestricted Stock Unit
7.7K shares- - Jan 2, 2026SMMT
Summit Therapeutics Inc.
Award(A)DirectStock Option (right to buy)
3.2K shares at avg. $8.76- - Jan 2, 2026SMMT
Summit Therapeutics Inc.
Award(A)DirectStock Option (right to buy)
35K shares- - Jul 18, 2025PBYI
PUMA BIOTECHNOLOGY, INC.
Sale(S)Direct27K shares at avg. $3.37$91K - Jun 13, 2025PBYI
PUMA BIOTECHNOLOGY, INC.
Sale(S)Direct12.2K shares at avg. $3.40$41K - Jun 11, 2025PBYI
PUMA BIOTECHNOLOGY, INC.
Award(A)Direct27K shares- - Jan 2, 2025SMMT
Summit Therapeutics Inc.
Award(A)DirectStock Option (right to buy)
35K shares- - Jan 2, 2025SMMT
Summit Therapeutics Inc.
Award(A)DirectStock Option (right to buy)
3.1K shares at avg. $9.18- - Dec 10, 2024ZYME
Zymeworks Inc.
Award(A)DirectStock Option (Right to Buy)
31K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Sep 14, 2026 |  PBYI PUMA BIOTECHNOLOGY, INC. | Exercise(M) | 50,000 | $2.93 | $146,500 | Direct |
| Sep 14, 2026 | PBYI PUMA BIOTECHNOLOGY, INC. | Sale(S) | 62,150 | $9.12 | $566,994 | Direct |
| Jun 11, 2026 | PBYI PUMA BIOTECHNOLOGY, INC. | Award(A) | 27,000 | - | $0 | Direct |
| Jan 12, 2026 |  ZYME Zymeworks Inc. | Award(A) Stock Option (Right to Buy) | 11,500 | - | - | Direct |
| Jan 12, 2026 | ZYME Zymeworks Inc. | Award(A) Restricted Stock Unit | 7,700 | - | - | Direct |
| Jan 2, 2026 |  SMMT Summit Therapeutics Inc. | Award(A) Stock Option (right to buy) | 3,219 | $8.76 | - | Direct |
| Jan 2, 2026 | SMMT Summit Therapeutics Inc. | Award(A) Stock Option (right to buy) | 35,000 | - | - | Direct |
| Jul 18, 2025 | PBYI PUMA BIOTECHNOLOGY, INC. | Sale(S) | 27,000 | $3.37 | $90,909 | Direct |
| Jun 13, 2025 | PBYI PUMA BIOTECHNOLOGY, INC. | Sale(S) | 12,150 | $3.40 | $41,310 | Direct |
| Jun 11, 2025 | PBYI PUMA BIOTECHNOLOGY, INC. | Award(A) | 27,000 | - | - | Direct |
| Jan 2, 2025 | SMMT Summit Therapeutics Inc. | Award(A) Stock Option (right to buy) | 35,000 | - | - | Direct |
| Jan 2, 2025 | SMMT Summit Therapeutics Inc. | Award(A) Stock Option (right to buy) | 3,073 | $9.18 | - | Direct |
| Dec 10, 2024 | ZYME Zymeworks Inc. | Award(A) Stock Option (Right to Buy) | 31,000 | - | - | Direct |
1-13 of 13 transactions
About Cesano Alessandra
Cesano Alessandra (SEC CIK 0001827015) files insider reports with the SEC as Director of PUMA BIOTECHNOLOGY, INC. (PBYI), Director of Zymeworks Inc. (ZYME) and Director of Summit Therapeutics Inc. (SMMT).
Signal8 holds 9 ownership filings by Cesano Alessandra, all Form 4s, filed between Dec 12, 2024 and Sep 16, 2026. Those filings report 13 transactions, from Dec 10, 2024 to Sep 14, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Cesano Alessandra's filings is in LOS ANGELES, CA.
Recent filings by Cesano Alessandra
- Sep 14, 2026: Option exercise of PBYI shares (Form 4, code M).
- Sep 14, 2026: Open-market sale of PBYI shares (Form 4, code S).
- Jun 11, 2026: Grant or award of PBYI shares (Form 4, code A).
- Jan 12, 2026: Grants or awards of ZYME derivative securities (2 lines, Form 4, code A).
- Jan 2, 2026: Grants or awards of SMMT derivative securities (2 lines, Form 4, code A).
Other insiders filing for PUMA BIOTECHNOLOGY, INC. (PBYI)
- WILSON TROY EDWARD, Director
- AUERBACH ALAN H, President and CEO
- HUNT DOUGLAS M
- NOUGUES MAXIMO F, Chief Financial Officer
- Stuglik Brian M, Director
- Senderowicz Adrian, Director